Syntara Limited
SNT.ASXHealth Care
Syntara Limited is a clinical stage drug development company with a focus on blood-related cancers. The company's highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors.
Market Data
$0.026
-0.0%$50.7M
-100000.0x
$-0.009
0.00%
-0.5%
Latest Earnings
Half Year Report and Appendix 4D
26 February 2026
Syntara Limited reported a loss of $5.9M for H1 FY25, significantly worse than the $2.7M loss in H1 FY24, primarily due to increased clinical trial expenses. The company received a $5.6M R&D tax incentive and made substantial progress advancing its clinical pipeline across multiple drug candidates, particularly in myelofibrosis and other blood cancers. Key points: Received $5.6M R&D tax incentive providing non-dilutive funding; Completed Phase 1a component of SNT-9465 hypertrophic scars trial with favorable safety and target engagement; Advanced amsulostat across multiple indications including myelofibrosis, MDS and pancreatic cancer with positive regulatory feedback
Recent Announcements
Half Year Report and Appendix 4D
Syntara Limited reported a loss of $5.9M for H1 FY25, significantly worse than the $2.7M loss in H1 FY24, primarily due to increased clinical trial expenses. The company received a $5.6M R&D tax incentive and made substantial progress advancing its clinical pipeline across multiple drug candidates, particularly in myelofibrosis and other blood cancers. Key points: Received $5.6M R&D tax incentive providing non-dilutive funding; Completed Phase 1a component of SNT-9465 hypertrophic scars trial with favorable safety and target engagement; Advanced amsulostat across multiple indications including myelofibrosis, MDS and pancreatic cancer with positive regulatory feedback
Get real-time alerts for SNT
Receive AI-powered earnings summaries and instant notifications when Syntara Limited releases results.
Register Free